IDEXX Laboratories, Inc. $IDXX Shares Sold by RFG Advisory LLC

RFG Advisory LLC decreased its holdings in IDEXX Laboratories, Inc. (NASDAQ:IDXX) by 49.4% in the 1st quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 1,332 shares of the company’s stock after selling 1,299 shares during the quarter. RFG Advisory LLC’s holdings in IDEXX Laboratories were worth $748,000 as of its most recent filing with the SEC.

A number of other hedge funds also recently added to or reduced their stakes in IDXX. Elyxium Wealth LLC acquired a new position in IDEXX Laboratories during the fourth quarter worth $3,666,459,000. J. Stern & Co. LLP raised its stake in shares of IDEXX Laboratories by 23,694.7% during the 4th quarter. J. Stern & Co. LLP now owns 2,653,351 shares of the company’s stock worth $1,795,072,000 after buying an additional 2,642,200 shares during the last quarter. Northwestern Mutual Wealth Management Co. raised its position in IDEXX Laboratories by 63,503.9% during the fourth quarter. Northwestern Mutual Wealth Management Co. now owns 1,444,445 shares of the company’s stock worth $977,210,000 after acquiring an additional 1,442,174 shares during the last quarter. Wellington Management Group LLP raised its position in shares of IDEXX Laboratories by 318.1% during the 4th quarter. Wellington Management Group LLP now owns 779,214 shares of the company’s stock worth $527,162,000 after purchasing an additional 592,834 shares during the last quarter. Finally, Norges Bank acquired a new position in shares of IDEXX Laboratories in the fourth quarter worth $332,265,000. 87.84% of the stock is owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

Several equities analysts recently issued reports on the stock. Wall Street Zen raised shares of IDEXX Laboratories from a “hold” rating to a “buy” rating in a research note on Saturday, June 13th. Stifel Nicolaus reduced their price objective on IDEXX Laboratories from $775.00 to $675.00 and set a “buy” rating on the stock in a research note on Tuesday, March 31st. Weiss Ratings upgraded shares of IDEXX Laboratories from a “hold (c)” rating to a “hold (c+)” rating in a report on Thursday. UBS Group decreased their price target on IDEXX Laboratories from $730.00 to $640.00 and set a “neutral” rating for the company in a report on Tuesday, April 28th. Finally, Citigroup started coverage on shares of IDEXX Laboratories in a research report on Wednesday, April 15th. They issued a “neutral” rating and a $650.00 price objective for the company. Seven equities research analysts have rated the stock with a Buy rating and four have assigned a Hold rating to the company. According to MarketBeat.com, IDEXX Laboratories presently has a consensus rating of “Moderate Buy” and a consensus target price of $751.00.

IDEXX Laboratories Stock Performance

Shares of IDEXX Laboratories stock opened at $551.50 on Monday. The company has a debt-to-equity ratio of 0.19, a quick ratio of 0.82 and a current ratio of 1.12. IDEXX Laboratories, Inc. has a 1 year low of $506.91 and a 1 year high of $769.98. The firm’s 50-day simple moving average is $558.79 and its 200-day simple moving average is $614.13. The firm has a market cap of $43.50 billion, a PE ratio of 40.61, a price-to-earnings-growth ratio of 3.02 and a beta of 1.56.

IDEXX Laboratories (NASDAQ:IDXX) last posted its quarterly earnings results on Tuesday, May 5th. The company reported $3.47 EPS for the quarter, topping analysts’ consensus estimates of $3.41 by $0.06. The business had revenue of $1.14 billion during the quarter, compared to the consensus estimate of $1.12 billion. IDEXX Laboratories had a return on equity of 70.87% and a net margin of 24.63%.The company’s revenue for the quarter was up 14.3% compared to the same quarter last year. During the same period last year, the firm earned $2.91 earnings per share. IDEXX Laboratories has set its FY 2026 guidance at 14.450-14.900 EPS. Equities analysts forecast that IDEXX Laboratories, Inc. will post 14.68 earnings per share for the current fiscal year.

About IDEXX Laboratories

IDEXX Laboratories, Inc (NASDAQ: IDXX) is a global developer, manufacturer and provider of diagnostic products and services primarily for the animal health, water testing and food safety markets. Headquartered in Westbrook, Maine, the company supplies in-clinic diagnostic instruments, consumables, reference laboratory testing and practice-management tools that support veterinarians, livestock and dairy producers, and utilities and food producers worldwide.

IDEXX’s product portfolio includes point-of-care tests and immunoassays designed for rapid diagnosis in veterinary clinics, in-clinic chemistry and hematology analyzers, automated urinalysis systems, and digital diagnostic solutions.